Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety and Immunogenicity When Co-administered With Routine EPI Vaccines in Infants Following Safety Assessment in Children Aged 2-4 Yrs in The Gambia.

Trial Profile

Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety and Immunogenicity When Co-administered With Routine EPI Vaccines in Infants Following Safety Assessment in Children Aged 2-4 Yrs in The Gambia.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Pneumococcal vaccine (Primary) ; Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix); Measles virus vaccine live; Pneumococcal 11-valent vaccine conjugate; Pneumococcal 13-valent CRM197 vaccine conjugate; Poliovirus vaccine live oral; Yellow fever vaccine
  • Indications Diphtheria; Measles; Pneumococcal infections; Poliomyelitis; Streptococcal infections; Tetanus; Yellow fever
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 04 Apr 2017 Results published in the Vaccine
    • 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top